Hereditary Angioedema Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Hereditary Angioedema Market to 2027 - Global Analysis and Forecasts By Drugs (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, Others); Route of Administration (Subcutaneous, Intravenous, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)

Report Code: TIPRE00005410 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Hereditary Angioedema is a rare disorder characterized by recurrent episodes of severe swelling in body parts like limbs, face, intestinal tract or airway. Minor trauma or stress may trigger an attack but swelling often occurs without a known trigger.

MARKET DYNAMICS
The Hereditary Angioedema market is anticipated to grow in the forecast, owing to the factors such as rise in hereditary angioedema attacks, increasing R&D initiatives by the manufacturers, presence of promising drug pipeline, and approval of novel therapies by the regulatory agencies. Nevertheless, lack of awareness regarding the disease, and high cost of the drugs are expected to restrict the market growth during the forecast period.

MARKET SCOPE
The "Global Hereditary Angioedema Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Hereditary Angioedema market with detailed market segmentation by Drugs, Route of Administration, Distribution Channel and geography. The global Hereditary Angioedema market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Hereditary Angioedema market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Hereditary Angioedema market is segmented on the basis of drugs, route of administration and distribution channel. Based on drugs the market is segmented into c1 esterase inhibitor, kallikrein inhibitor, bradykinin receptor, attenuated androgens, and others. Based on route of administration the market is segmented into subcutaneous, intravenous, and oral. Based on distribution channel the market is segmented into hospital pharmacies, retail pharmacies, and e-commerce.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Hereditary Angioedema market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Hereditary Angioedema market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Hereditary Angioedema market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Hereditary Angioedema market in these regions.

MARKET PLAYERS
The reports cover key developments in the Hereditary Angioedema market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Hereditary Angioedema market are anticipated to lucrative growth opportunities in the future with the rising demand for Hereditary Angioedema market in the global market. Below mentioned is the list of few companies engaged in the Hereditary Angioedema market.

The report also includes the profiles of Hereditary Angioedema market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • BIOCRYST PHARMACEUTICALS, INC
  • CSL
  • Ionis Pharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp
  • Pharming Group N.V.
  • Sanofi N.V.
  • Shire plc.
  • Teva Pharmaceutical Industries, Ltd.
  • Attune Pharmaceuticals
  • KalVista Pharmaceuticals, Inc
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Hereditary Angioedema Market - By Drugs
1.3.2 Hereditary Angioedema Market - By Route of Administration
1.3.3 Hereditary Angioedema Market - By Distribution Channel
1.3.4 Hereditary Angioedema Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HEREDITARY ANGIOEDEMA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. HEREDITARY ANGIOEDEMA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HEREDITARY ANGIOEDEMA MARKET - GLOBAL MARKET ANALYSIS
6.1. HEREDITARY ANGIOEDEMA - GLOBAL MARKET OVERVIEW
6.2. HEREDITARY ANGIOEDEMA - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. C1 ESTERASE INHIBITOR
7.3.1. Overview
7.3.2. C1 Esterase Inhibitor Market Forecast and Analysis
7.4. KALLIKREIN INHIBITOR
7.4.1. Overview
7.4.2. Kallikrein Inhibitor Market Forecast and Analysis
7.5. BRADYKININ RECEPTOR
7.5.1. Overview
7.5.2. Bradykinin Receptor Market Forecast and Analysis
7.6. ATTENUATED ANDROGENS
7.6.1. Overview
7.6.2. Attenuated Androgens Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. SUBCUTANEOUS
8.3.1. Overview
8.3.2. Subcutaneous Market Forecast and Analysis
8.4. INTRAVENOUS
8.4.1. Overview
8.4.2. Intravenous Market Forecast and Analysis
8.5. ORAL
8.5.1. Overview
8.5.2. Oral Market Forecast and Analysis
9. HEREDITARY ANGIOEDEMA MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. E-COMMERCE
9.5.1. Overview
9.5.2. E-Commerce Market Forecast and Analysis
10. HEREDITARY ANGIOEDEMA MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Hereditary Angioedema Market Overview
10.1.2 North America Hereditary Angioedema Market Forecasts and Analysis
10.1.3 North America Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.1.4 North America Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.1.6.1 United States Hereditary Angioedema Market
10.1.6.1.1 United States Hereditary Angioedema Market by Drugs
10.1.6.1.2 United States Hereditary Angioedema Market by Route of Administration
10.1.6.1.3 United States Hereditary Angioedema Market by Distribution Channel
10.1.6.2 Canada Hereditary Angioedema Market
10.1.6.2.1 Canada Hereditary Angioedema Market by Drugs
10.1.6.2.2 Canada Hereditary Angioedema Market by Route of Administration
10.1.6.2.3 Canada Hereditary Angioedema Market by Distribution Channel
10.1.6.3 Mexico Hereditary Angioedema Market
10.1.6.3.1 Mexico Hereditary Angioedema Market by Drugs
10.1.6.3.2 Mexico Hereditary Angioedema Market by Route of Administration
10.1.6.3.3 Mexico Hereditary Angioedema Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Hereditary Angioedema Market Overview
10.2.2 Europe Hereditary Angioedema Market Forecasts and Analysis
10.2.3 Europe Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.2.4 Europe Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Hereditary Angioedema Market
10.2.6.1.1 Germany Hereditary Angioedema Market by Drugs
10.2.6.1.2 Germany Hereditary Angioedema Market by Route of Administration
10.2.6.1.3 Germany Hereditary Angioedema Market by Distribution Channel
10.2.6.2 France Hereditary Angioedema Market
10.2.6.2.1 France Hereditary Angioedema Market by Drugs
10.2.6.2.2 France Hereditary Angioedema Market by Route of Administration
10.2.6.2.3 France Hereditary Angioedema Market by Distribution Channel
10.2.6.3 Italy Hereditary Angioedema Market
10.2.6.3.1 Italy Hereditary Angioedema Market by Drugs
10.2.6.3.2 Italy Hereditary Angioedema Market by Route of Administration
10.2.6.3.3 Italy Hereditary Angioedema Market by Distribution Channel
10.2.6.4 Spain Hereditary Angioedema Market
10.2.6.4.1 Spain Hereditary Angioedema Market by Drugs
10.2.6.4.2 Spain Hereditary Angioedema Market by Route of Administration
10.2.6.4.3 Spain Hereditary Angioedema Market by Distribution Channel
10.2.6.5 United Kingdom Hereditary Angioedema Market
10.2.6.5.1 United Kingdom Hereditary Angioedema Market by Drugs
10.2.6.5.2 United Kingdom Hereditary Angioedema Market by Route of Administration
10.2.6.5.3 United Kingdom Hereditary Angioedema Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Hereditary Angioedema Market Overview
10.3.2 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis
10.3.3 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.3.4 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Hereditary Angioedema Market
10.3.6.1.1 Australia Hereditary Angioedema Market by Drugs
10.3.6.1.2 Australia Hereditary Angioedema Market by Route of Administration
10.3.6.1.3 Australia Hereditary Angioedema Market by Distribution Channel
10.3.6.2 China Hereditary Angioedema Market
10.3.6.2.1 China Hereditary Angioedema Market by Drugs
10.3.6.2.2 China Hereditary Angioedema Market by Route of Administration
10.3.6.2.3 China Hereditary Angioedema Market by Distribution Channel
10.3.6.3 India Hereditary Angioedema Market
10.3.6.3.1 India Hereditary Angioedema Market by Drugs
10.3.6.3.2 India Hereditary Angioedema Market by Route of Administration
10.3.6.3.3 India Hereditary Angioedema Market by Distribution Channel
10.3.6.4 Japan Hereditary Angioedema Market
10.3.6.4.1 Japan Hereditary Angioedema Market by Drugs
10.3.6.4.2 Japan Hereditary Angioedema Market by Route of Administration
10.3.6.4.3 Japan Hereditary Angioedema Market by Distribution Channel
10.3.6.5 South Korea Hereditary Angioedema Market
10.3.6.5.1 South Korea Hereditary Angioedema Market by Drugs
10.3.6.5.2 South Korea Hereditary Angioedema Market by Route of Administration
10.3.6.5.3 South Korea Hereditary Angioedema Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Hereditary Angioedema Market Overview
10.4.2 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis
10.4.3 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.4.4 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Hereditary Angioedema Market
10.4.6.1.1 South Africa Hereditary Angioedema Market by Drugs
10.4.6.1.2 South Africa Hereditary Angioedema Market by Route of Administration
10.4.6.1.3 South Africa Hereditary Angioedema Market by Distribution Channel
10.4.6.2 Saudi Arabia Hereditary Angioedema Market
10.4.6.2.1 Saudi Arabia Hereditary Angioedema Market by Drugs
10.4.6.2.2 Saudi Arabia Hereditary Angioedema Market by Route of Administration
10.4.6.2.3 Saudi Arabia Hereditary Angioedema Market by Distribution Channel
10.4.6.3 U.A.E Hereditary Angioedema Market
10.4.6.3.1 U.A.E Hereditary Angioedema Market by Drugs
10.4.6.3.2 U.A.E Hereditary Angioedema Market by Route of Administration
10.4.6.3.3 U.A.E Hereditary Angioedema Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Hereditary Angioedema Market Overview
10.5.2 South and Central America Hereditary Angioedema Market Forecasts and Analysis
10.5.3 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Drugs
10.5.4 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Hereditary Angioedema Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Hereditary Angioedema Market
10.5.6.1.1 Brazil Hereditary Angioedema Market by Drugs
10.5.6.1.2 Brazil Hereditary Angioedema Market by Route of Administration
10.5.6.1.3 Brazil Hereditary Angioedema Market by Distribution Channel
10.5.6.2 Argentina Hereditary Angioedema Market
10.5.6.2.1 Argentina Hereditary Angioedema Market by Drugs
10.5.6.2.2 Argentina Hereditary Angioedema Market by Route of Administration
10.5.6.2.3 Argentina Hereditary Angioedema Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. HEREDITARY ANGIOEDEMA MARKET, KEY COMPANY PROFILES
12.1. BIOCRYST PHARMACEUTICALS, INC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CSL
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. IONIS PHARMACEUTICALS, INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. MERCK SHARP AND DOHME CORP
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PHARMING GROUP N.V
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SANOFI N.V
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SHIRE PLC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TEVA PHARMACEUTICAL INDUSTRIES, LTD
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ATTUNE PHARMACEUTICALS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. KALVISTA PHARMACEUTICALS, INC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- BIOCRYST PHARMACEUTICALS, INC
- CSL
- Ionis Pharmaceuticals, Inc.
- Merck Sharp & Dohme Corp
- Pharming Group N. V.
- Sanofi N. V.
- Shire plc.
- Teva Pharmaceutical Industries, Ltd.
- Attune Pharmaceuticals
- KalVista Pharmaceuticals, Inc